Roger Bate is a Resident Scholar at the American Enterprise Institute. He researches international health policy, with a special interest in counterfeit and substandard medicines and malaria control. He has a PhD in economics from Cambridge University. Dr. Bate’s writings have appeared in, among others the: New York Times, Washington Post, Wall Street Journal, Financial Times, Lancet, PLoS Medicine, Journal of Health Economics, Malaria Journal, and British Medical Journal. He regularly contributes to AEI’s Health Policy Outlook series. He has been an advisor to the South African Government.
Dr Bate conducted extensive research in India and numerous Africa countries on the public health consequences of the counterfeit drug trade. His latest book is Phake: The Deadly World of Falsified and Substandard Medicine (AEI Press, May 2012). He is the author or editor of 14 books and over 1,000 journal and newspaper articles.
His broader interests include aid policy in Africa and the developing world, evaluating the performance and effectiveness of WHO, USAID, the World Bank, , NGOs, and other aid organizations and development policy initiatives. He writes extensively on topics such as endemic diseases in developing countries (malaria, HIV/AIDS); access and innovation in pharmaceuticals; taxes and tariffs; water policy; and international health agreements.
Dr. Bate was the founder of the Frederic Bastiat Journalism Prize, co-founder with Richard Tren of Africa Fighting Malaria, where he remains on the board of directors. He is also a fellow at the Institute of Economic Affairs in London.
Recent Posts by Roger Bate
Poorly manufactured and fraudulent medicines kill thousands of people around the world each year. For infectious diseases like malaria and HIV, shoddy medicines also accelerate drug resistance and dramatically alter the course of epidemics. With few new drugs under development, recent progress...
From fake Avastin to contaminated generic Lipitor, every month Americans are becoming more aware about the dangers of lethal products they might be unlucky enough to take. With attentive regulators and competent companies, most incidents of dangerous drugs in US pass without significant harm,...